CClinicalTrials.gg
Sign In
RecruitingNCT07724366Updated Sep 9, 2026

A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of TQH3906 capsules and Deucravacitinib tablets 6 mg in Psoriasis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 45 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group. The study aims to evaluate the efficacy and safety of once-daily oral TQH3906 capsules (24 mg) in adult participants with moderate to severe plaque psoriasis. TQH3906 is a highly selective TYK2 allosteric inhibitor targeting the JH2 domain, which blocks the IL-23 and Type I interferon inflammatory pathways. Approximately 400 eligible participants aged 18-75 years will be enrolled. Participants will be stratified based on prior biologic use and randomized in a 2:2:1 ratio to the TQH3906 group, the deucravacitinib active control group, or the placebo group. The trial includes a screening period, a 16-week double-blind controlled treatment phase, a 36-week open-label extension phase (during which all participants will receive TQH3906), and a 4-week safety follow-up after the last dose. The co-primary endpoints are the proportion of participants achieving sPGA 0/1 and PASI 90 response at Week 16. Secondary endpoints include improvements in scalp, nail, and palmoplantar psoriasis, Dermatology Life Quality Index (DLQI), long-term safety, and steady-state pharmacokinetic parameters. This study will collect comprehensive efficacy and safety data over 52 weeks to support the New Drug Application (NDA) for TQH3906 for the treatment of plaque psoriasis.

02

Conditions studied

  • Psoriasis

Browse trials for

03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:1. Participants must be between 18 and 75 years old when signing the informed consent form (ICF), regardless of gender; 2. Confirmed diagnosis of plaque psoriasis for at least 6 months at screenin 3. Disease is stable at screening and baseline visits, and the following criteria are met:

  • Static Physician Global Assessment (sPGA) score ≥3;
  • Psoriasis Area and Severity Index (PASI) score ≥12;
  • Body Surface Area (BSA) affected by psoriasis ≥10%; 4. Deemed by the Investigator as suitable for systemic therapy or phototherapy; 5. Women of childbearing potential must have a negative pregnancy test at screening and baseline visits. Women of childbearing potential and male trial participants whose spouse or partner is a woman of childbearing potential must be willing to use at least one effective method of contraception as specified in the protocol during the study period (from signing the ICF until 30 days after the last dose of investigational drug). Male trial participants must also commit to not donating sperm during the study period and within 30 days after the last dose of study drug; 6. Before initiating any screening or study-specific procedures, trial participants must be able to understand and willing to comply with all protocol requirements, and voluntarily sign and date the ICF.

Exclusion Criteria:1.Presence of non-plaque psoriasis during the Screening period or at the Baseline visit; 2.Past or current diagnosis of drug-induced psoriasis; 3.Concomitant other autoimmune diseases, including but not limited to rheumatoid arthritis, sarcoidosis, and systemic lupus erythematosus; 4.Receiving therapeutic agents for psoriatic arthritis (PsA) other than stable-dose non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics.

5.Prior exposure to TQH3906 Capsules or Deucravacitinib Tablets; 6.Receipt of any of the following medications or treatments within the specified time window:

  1. Any topical agents or treatments that may interfere with psoriasis assessment, administered within 2 weeks before the Baseline visit;
  2. Psoriasis phototherapy administered within 4 weeks before the Baseline visit;
  3. Any biologics or biosimilars thereof, administered within the specified time frame before the Baseline visit;
  4. Systemic non-biologic psoriasis therapy and/or systemic immunosuppressive treatment administered within 4 weeks before the Baseline visit; 5) Within 6 months prior to the baseline visit: Leflunomide; 6) Within 4 weeks prior to the baseline visit: Traditional Chinese medicines (TCM), Chinese proprietary medicines, or herbal preparations used for psoriasis treatment or with unknown composition/nature, including but not limited to Total Glucosides of Paeony, Tripterygium wilfordii preparations, Compound Glycyrrhizin preparations, Compound Qingdai preparations, etc.; 7) Within 4 weeks prior to the baseline visit: Any live vaccines or live-attenuated vaccines; OR anticipated need to receive live vaccines or live-attenuated vaccines during the study period including at least 4 weeks after the last dose of investigational product; 8) Within 3 months prior to the baseline visit (or 5 half-lives, whichever is longer): Investigational biological agent treatment; OR within 30 days prior to the baseline visit (or 5 half-lives, whichever is longer): Any other investigational drug treatment; OR currently participating in other clinical trials; 7. Active infection/history of infection, or receipt of specific anti-infective therapies within the specified time windows; 8. Previous or current presence of severe or unstable diseases or medical conditions involving neurological, cardiovascular, respiratory, digestive, urinary, hematological, or immune systems that, in the Investigator's judgment, may interfere with outcome assessment or affect participation safety 9. Laboratory test abnormalities meeting any of the following criteria during the screening period: 1) Hemoglobin \<90.0 g/L; 2) White blood cell count \<3.0×10⁹/L; 3) Neutrophil count \<1.0×10⁹/L; 4) Lymphocyte count \<0.5×10⁹/L; 5) Platelet count \<100×10⁹/L; 6) Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) >3× Upper Limit of Normal (ULN); 7) Total bilirubin (TBIL) >1.5× ULN; 8) Estimated creatinine clearance \<45 mL/min calculated based on the Cockcroft-Gault formula. (See Appendix 2 for calculation formula); 9) Thyroid-stimulating hormone (TSH) outside the normal reference range, concomitant with free T4 or T3 also outside the normal reference range.

10. History of drug or alcohol abuse within 6 months prior to screening; 11. Known allergy, hypersensitivity, or intolerance to TQH3906 capsules, deucravacitinib tablets, or any excipient ingredients; 12. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial, and men who plan to father children or donate sperm during the trial; 13. Trial participants who are employees of the Sponsor, third-party agency staff, or direct research center staff involved in this study or their family members; 14. Per Investigator assessment, presence of any other medical, psychiatric, or other reasons that render the trial participant unsuitable for participation in this study.

-

04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    TQH3906 Capsules + Deucravacitinib tablets placebo

    Double-blind phase: TQH3906 capsule 24 mg + deucravacitinib tablet placebo; Open-label extension phase: TQH3906 capsule 24 mg monotherapy.

    Drug: TQH3906 capsules · Drug: Deucravacitinib tablets placebo

  • Active comparator
    TQH3906 Capsules placebo + Deucravacitinib tablets 6 mg

    Double-blind phase: TQH3906 capsule placebo + deucravacitinib tablet 6 mg; Open-label extension phase: TQH3906 capsule 24 mg monotherapy.

    Drug: Deucravacitinib tablets 6 mg · Drug: TQH3906 Capsules placebo

  • Placebo comparator
    TQH3906 Capsules placebo + Deucravacitinib tablets placebo

    Double-blind phase: TQH3906 capsule placebo + Deucravacitinib tablet placebo; Open-label extension phase: TQH3906 capsule 24 mg monotherapy.

    Drug: TQH3906 Capsules placebo · Drug: Deucravacitinib tablets placebo

Interventions

  • DrugTQH3906 capsules

    TQH3906 Capsules is an inhibitor that targets tyrosine kinase 2 (TYK2).

  • DrugDeucravacitinib tablets 6 mg

    Deucravacitinib tablet is an inhibitor that targets tyrosine kinase 2 (TYK2).

  • DrugTQH3906 Capsules placebo

    No pharmacologically active substance

  • DrugDeucravacitinib tablets placebo

    No pharmacologically active substance

05

What researchers measure

Primary outcomes

  1. static Physician's Global Assessment (sPGA)

    Proportion of participants achieving sPGA 0/1 at Week 16, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 16 weeks

  2. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 90 at Week 16, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 16 weeks

Secondary outcomes

  1. static Physician's Global Assessment (sPGA)

    Proportion of participants achieving sPGA 0/1 at Week 16, comparing participants using TQH3906 capsules versus Deucravacitinib..

    Time frame: Baseline up to 16 weeks

  2. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 90 at Week 16, comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 16 weeks

  3. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 75 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  4. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 75 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  5. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 90 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  6. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 90 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  7. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 100 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  8. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 100 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  9. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 50 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  10. Psoriasis Area and Severity Index (PASI)

    Proportion of participants achieving PASI 50 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  11. Psoriasis Area and Severity Index (PASI)

    Change from baseline in PASI scores and percent change at each assessment visit; comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  12. Psoriasis Area and Severity Index (PASI)

    Change from baseline in PASI scores and percent change at each assessment visit; comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  13. Psoriasis Area and Severity Index (PASI)

    The proportion of trial participants achieving PASI score \< 3 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  14. Psoriasis Area and Severity Index (PASI)

    The proportion of trial participants achieving PASI score \< 3 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  15. static Physician's Global Assessment (sPGA)

    Proportion of participants achieving sPGA 0/1 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  16. static Physician's Global Assessment (sPGA)

    Proportion of participants achieving sPGA 0/1 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib..

    Time frame: Baseline up to 52 weeks

  17. static Physician's Global Assessment (sPGA)

    Proportion of participants achieving sPGA 0 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  18. Scalp static Physician's Global Assessment (sPGA)

    Proportion of participants achieving sPGA 0 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib..

    Time frame: Baseline up to 52 weeks

  19. Scalp static Physician's Global Assessment (ssPGA)

    Proportion of participants achieving ssPGA 0/1 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  20. Scalp static Physician's Global Assessment (ssPGA)

    Proportion of participants achieving ssPGA 0/1 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib..

    Time frame: Baseline up to 52 weeks

  21. Palmoplantar Psoriasis Physician Global Assessment (pp-PGA)

    Proportion of participants achieving ssPGA 0/1 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  22. Palmoplantar Psoriasis Physician Global Assessment (pp-PGA)

    Proportion of participants achieving pp-PGA 0/1 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib..

    Time frame: Baseline up to 52 weeks

  23. Physician's Global Assessment of Fingernail Psoriasis (PGA-F)

    Proportion of participants achieving PGA-F 0/1 at each assessment visits, comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  24. Physician's Global Assessment of Fingernail Psoriasis (PGA-F)

    Proportion of participants achieving PGA-F 0/1 at each assessment visits, comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  25. Dermatology Life Quality Index (DLQI)

    Change from baseline in Dermatology Life Quality Index (DLQI) at each assessment visit;comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  26. Dermatology Life Quality Index (DLQI)

    Change from baseline in Dermatology Life Quality Index (DLQI) at each assessment visit;comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  27. Dermatology Life Quality Index (DLQI)

    Proportion of participants achieving DLQI 0/1 at each assessment visit;comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  28. Dermatology Life Quality Index (DLQI)

    Proportion of participants achieving DLQI 0/1 at each assessment visit;comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  29. Psoriatic Lesion Body Surface Area (BSA)

    Change from baseline in Psoriatic Lesion Body Surface Area (BSA) at each assessment visit; comparing participants using TQH3906 capsules versus placebo.

    Time frame: Baseline up to 52 weeks

  30. Psoriatic Lesion Body Surface Area (BSA)

    Change from baseline in Psoriatic Lesion Body Surface Area (BSA) at each assessment visit; comparing participants using TQH3906 capsules versus Deucravacitinib.

    Time frame: Baseline up to 52 weeks

  31. Effects on participants' Psoriasis Area and Severity Index (PASI)

    Questionnaire: Psoriasis Area and Severity Index (PASI) total score, range 0-72. The body is divided into 4 regions (head, upper extremities, trunk, lower extremities) weighted by 0.1, 0.2, 0.3, 0.4 respectively. Each region is scored for erythema, induration, desquamation (0-4 each) and lesion area (0-6). Higher scores indicate more severe psoriasis.

    Time frame: Baseline up to 52 weeks

  32. Effects on participants' static Physician's Global Assessment (sPGA)

    Questionnaire: Static Physician's Global Assessment (sPGA) is a single-item static global severity scale (0-4 points) assessing overall psoriasis lesion severity at a single timepoint, based on equal-weighted evaluation of 3 lesion features: erythema, induration, desquamation (each scored 0-4, averaged to final global score). Scoring grading: 0 = Cleared (no active lesions, residual pigmentation allowed) 1. = Almost cleared 2. = Mild 3. = Moderate 4. = Severe sPGA 0/1 responder = score 0 or 1 at target visit;

    Time frame: Baseline up to 52 weeks

  33. Effects on participants' Scalp static Physician's Global Assessment (ssPGA)

    Questionnaire: ssPGA is a static 5-point single-item scale (0 to 4) exclusively evaluating scalp psoriatic lesions, comprehensively and equally assessing three lesion features: erythema, plaque induration/thickening, and scaling limited to scalp only. Scoring grading: 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe

    Time frame: Baseline up to 52 weeks

  34. Effects on participants' Palmoplantar Psoriasis Physician Global Assessment (pp-PGA)

    Questionnaire: Palmoplantar Psoriasis Physician Global Assessment (pp-PGA). is a static single-item 5-point scale (score range 0-4), exclusively evaluating plaque psoriasis lesions limited to palms and soles. Investigators equally assess three core lesion features: erythema, hyperkeratosis/induration, scaling (fissures/pain secondary to plaques are referenced as auxiliary manifestations). Grading definition: 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe

    Time frame: Baseline up to 52 weeks

  35. Effects on participants' Physician's Global Assessment of Fingernail Psoriasis (PGA-F)

    Questionnaire: Physician's Global Assessment of Fingernail Psoriasis (PGA-F) is a static single-item 5-point scale (score range 0-4), exclusively evaluating psoriatic lesions of all fingernails. Investigators comprehensively assess core nail psoriasis manifestations: nail pitting, onycholysis, subungual hyperkeratosis, splinter hemorrhages, nail discoloration, crumbling. Grading definition: 0 = Clear 1. = Almost clear 2. = Mild 3. = Moderate 4. = Severe

    Time frame: Baseline up to 52 weeks

  36. Effects on participants' Dermatology Life Quality Index (DLQI)

    Questionnaire: The Dermatology Life Quality Index (DLQI) is a validated self-administered 10-item patient-reported questionnaire evaluating the impact of skin disease on quality of life over the prior 7 days. The scale covers 6 domains: symptoms \& feelings, daily activities, leisure, work/school, personal relationships, treatment burden. Each question is scored 0 (not at all/not relevant) to 3 (very much); total score ranges from 0 to 30. Lower scores indicate less impairment to quality of life.

    Time frame: Baseline up to 52 weeks

  37. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) ,Adverse Events of Special Interest (AESIs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 56 weeks

  38. Plasma concentration of TQH3906 at steady state (Cav, SS)

    The plasma concentration at which the rate of administration and rate of elimination are in equilibrium.

    Time frame: 1 hour Pre-dose of day 1 and 30 minutes Pre-dose of day 29, day 57, day 113, day 225, day 365 during treatment.

06

Study locations

13 of 45 sites recruiting
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
    Not yet recruiting
  • The First Affiliated Hospital of Chongqing Medical University 。
    Chongqing, Chongqing Municipality 400010, China
    Not yet recruiting
  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing Municipality 400011, China
    Not yet recruiting
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510000, China
    Not yet recruiting
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 519041, China
    Not yet recruiting
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518032, China
    Recruiting
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
    Not yet recruiting
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou 550002, China
    Not yet recruiting
  • Hainan Fifth People's Hospital
    Haikou, Hainan 570100, China
    Not yet recruiting
  • Affiliated Hospital of Chengde Medical University
    Chengde, Hebei 067000, China
    Recruiting
  • Shijiazhuang Traditional Chinese Medicine Hospital
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
  • Heilongjiang Provincial Hospital
    Harbin, Heilongjiang 150036, China
    Recruiting
  • The Second Affiliated Hospital of Henan University of science and technology
    Luoyang, Henan 471099, China
    Not yet recruiting
  • Puyang Oilfield General Hospital
    Puyang, Henan 457001, China
    Not yet recruiting
  • Zhengzhou Central Hospital
    Zhengzhou, Henan 450000, China
    Not yet recruiting
  • The First Peopel's Hospital of Zhengzhou
    Zhengzhou, Henan 450004, China
    Not yet recruiting
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
    Recruiting
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
    Not yet recruiting
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
    Recruiting
  • Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 10010, China
    Not yet recruiting
  • The First People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222061, China
    Not yet recruiting
  • Chinese Academy of Medical Sciences Hospital for Skin Diseases
    Nanjing, Jiangsu 210042, China
    Withdrawn
  • Nantong Cancer Hospital
    Nantong, Jiangsu 215004, China
    Not yet recruiting
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 215002, China
    Recruiting
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212008, China
    Recruiting
  • The Second Hospital of Jilin University
    Changchun, Jilin 130000, China
    Not yet recruiting
  • Zhongyi Northeast International Hospital Co., Ltd.
    Shengyang, Liaoning 110623, China
    Recruiting
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110002, China
    Recruiting
  • Shenyang Seventh People's Hospital (Shenyang Hospital of Integrated Traditional Chinese and Western Medicine, Shenyang Dermatology Hospital)
    Shenyang, Liaoning 110003, China
    Withdrawn
  • Central Hospital Affiliated to Shenyang Medical College
    Shenyang, Liaoning 110023, China
    Not yet recruiting
  • The First People's Hospital of Xining
    Xining, Qinghai 810000, China
    Not yet recruiting
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
    Not yet recruiting
  • Qilu Hospital Dezhou Branch of Shandong University (Dezhou People's Hospital)
    Dezhou, Shandong 253000, China
    Recruiting
  • Jining No.1 People'S Hospital
    Jining, Shandong 272011, China
    Not yet recruiting
  • Qingdao Municipal Hospital
    Qingdao, Shandong 266000, China
    Not yet recruiting
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200040, China
    Not yet recruiting
  • The Second People's Hospital of ChangZhi
    Changzhi, Shanxi 46000, China
    Not yet recruiting
  • Suining Central Hospital
    Suining, Sichuan 629000, China
    Recruiting
  • Gerneral Hospital of Ningxia Medical Univercity
    Yinchuan, The Ningxia Hui Autonomous Region 750000, China
    Not yet recruiting
  • Tianjin First Central Hospital
    Tianjin, Tianjin Municipality 300110, China
    Not yet recruiting
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin Municipality 300120, China
    Not yet recruiting
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
    Not yet recruiting
  • Jiaxing First Hospital
    Jiaxing, Zhejiang 314001, China
    Not yet recruiting
  • Jinhua Municipal Central Hospital
    Jinhua, Zhejiang 321000, China
    Recruiting
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang 315020, China
    Recruiting
07

Registry details

Key details

Study ID
NCT07724366
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Sep 2, 2026
Primary completion
Sep 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 9, 2026

Study contacts

Xinghua Gao, Doctor
Contact
gaobarry@hotmail.com
13940152467

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Psoriasis→

Other studies from this sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Start the discussion